Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: vestor who wrote (1701)	9/7/2000 9:19:54 AM
From: Thure Meyer	Read Replies (1) \| Respond to of 1837

There is an article in today's NYTIMES about more collusion in the drug industry to keep competitors at bay. Interestingly it involves Taxol, which I believe Duramed is also working on. Although this is of tangential interest only, nevertheless it helps shape the regulatory and legal climate in favor of their Premarin allegations. "Drug Companies Suspected of Stifling Competition By MELODY PETERSEN The Federal Trade Commission said yesterday that it was investigating whether Bristol-Myers Squibb and a small California company called American Bioscience might have illegally colluded to keep the lower-cost, generic version of Bristol's top-selling cancer drug, Taxol, off the market. ...." The link is: nytimes.com Thure